BioCryst Pharmaceuticals, Inc.

BMV:BCRX * Stock Report

Market Cap: Mex$32.0b

BioCryst Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

BioCryst Pharmaceuticals's earnings have been declining at an average annual rate of -8%, while the Biotechs industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 45.7% per year.

Key information

-8.0%

Earnings growth rate

0.3%

EPS growth rate

Biotechs Industry Growth12.9%
Revenue growth rate45.7%
Return on equityn/a
Net Margin-30.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How BioCryst Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BMV:BCRX * Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24413-1242500
30 Jun 24382-1462350
31 Mar 24355-2092250
31 Dec 23331-2272140
30 Sep 23318-2362000
30 Jun 23307-2431860
31 Mar 23290-2261730
31 Dec 22271-2471590
30 Sep 22238-1931520
30 Jun 22204-2101430
31 Mar 22188-1941310
31 Dec 21157-1841190
30 Sep 21114-227970
30 Jun 2179-214870
31 Mar 2132-209740
31 Dec 2018-183630
30 Sep 2054-125520
30 Jun 2049-116470
31 Mar 2048-115420
31 Dec 1949-109370
30 Sep 1912-134310
30 Jun 1912-126270
31 Mar 1923-107330
31 Dec 1821-101300
30 Sep 1822-93300
30 Jun 1829-79250
31 Mar 1820-77140
31 Dec 1725-66140
30 Sep 1730-51120
30 Jun 1729-47110
31 Mar 1731-47110
31 Dec 1626-55110
30 Sep 1622-69110
30 Jun 1625-72110
31 Mar 1646-51120
31 Dec 1548-43130
30 Sep 1549-37120
30 Jun 1541-31110
31 Mar 1517-50100
31 Dec 1414-4570
30 Sep 1419-3970
30 Jun 1418-3870
31 Mar 1417-3660
31 Dec 1317-3060

Quality Earnings: BCRX * is currently unprofitable.

Growing Profit Margin: BCRX * is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BCRX * is unprofitable, and losses have increased over the past 5 years at a rate of 8% per year.

Accelerating Growth: Unable to compare BCRX *'s earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BCRX * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.1%).


Return on Equity

High ROE: BCRX *'s liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 12:57
End of Day Share Price 2024/11/11 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioCryst Pharmaceuticals, Inc. is covered by 30 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Tazeen AhmadBofA Global Research
Dae Gon HaBTIG